FOLH1 and metastatic prostate carcinoma: Not surprisingly, the radiation exposure of [89Zr]Zr-PSMA-617 PET/CT did not induce any of the side effects which have been reported for targeted radiotherapy of metastatic prostate cancer with PSMA-ligands, e.g., dry mouth and mucositis.